The company said that it is working in close alliance with local authorities to secure approval at the quickest time.
China Biologic, which had planned to begin preparation work for the project in late 2012 and complete the project by mid 2014, is now considering to stop production at its existing production facility in Guizhou by the end of 2013 as more stringent Good Manufacturing Practice (GMP) standard enacted by China’s State Food and Drug Administration comes into effect.
China Biologic is also evaluating the possible consequences of production suspension in Guizhou and the delay of the construction of the new facility as well as the possible reduction in sales revenue and possible additional investment in GMP upgrading.
The company is also considering to reallocate certain production resources, options to build up inventory and the feasibility of adjusting shipping plans for 2013 to cut down expected negative impacts and ensure supply continuity.